Aquestive Therapeutics Strategy and Business Model

Executive Overview

Aquestive Therapeutics is a U.S. specialty pharmaceutical company built around thin-film drug-delivery technology and late-stage reformulation programs. Headquartered in Warren, New Jersey, with manufacturing operations in Portage, Indiana, the company traces its roots to 2004 and focuses on situations where route of administration materially changes usability, speed, or patient adherence. Its core platform, PharmFilm, is designed to deliver medicines through oral soluble, buccal, or sublingual films, which can matter when swallowing is difficult, needles are undesirable, or portability is important. Aquestive’s commercial and development focus has centered on central nervous system rescue therapies and severe allergic reactions. Its key approved proprietary products include Sympazan, and, as of April 2024, Libervant for seizure clusters in children ages 2 to 5. Its most important pipeline asset is Anaphylm, a needle-free epinephrine sublingual film candidate for severe allergic reactions, including anaphylaxis. Unlike many small biopharmas, Aquestive also generates revenue from partnered products, manufacturing, licensing, and royalties tied to its delivery technology. That gives it a hybrid model: part specialty pharma company, part drug-delivery platform and supply partner. In fiscal 2023, Aquestive reported revenue of about $52 million.

Aquestive Therapeutics at a Glance

Logo
Common name	Aquestive Therapeutics
Full legal name	Aquestive Therapeutics, Inc.
Headquarters	Warren, New Jersey, United States
Ownership	Public company (Nasdaq: AQST)
Ticker	AQST
Exchange	NASDAQ
Market Cap	$621.61M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Roots trace to 2004; adopted the Aquestive Therapeutics name in 2016; initial public offering in 2018; Sympazan approved in 2018; Exservan approved in 2019; Libervant approved for patients ages 2 to 5 in 2024
Industry or industries	Specialty pharmaceuticals; drug delivery; central nervous system therapies; emergency allergy therapeutics
Key products or services	Sympazan, Libervant, PharmFilm drug-delivery technology, partnered manufacturing and licensing, royalty-bearing product relationships, Anaphylm pipeline program
Geographic footprint	Primarily United States, with selective international reach through partners and licensed products
Business segments as officially reported	One reportable segment
Company website	https://www.aquestive.com/

1. What Is the Strategy of Aquestive Therapeutics?

Aquestive’s public strategy, as reflected in its 2023 annual report, 2024 investor materials, and earnings commentary, is to build a higher-value specialty pharmaceutical business around differentiated delivery formats rather than compete as a broad, discovery-heavy drug developer. The company is concentrating on products where formulation and route of administration are the main source of advantage, especially in rescue situations and specialty central nervous system indications.

1a. What is the winning aspiration of Aquestive Therapeutics?

Aquestive’s winning aspiration is to turn its delivery technology into commercially meaningful proprietary products, not just partner revenue. In practical terms, that means moving the company toward a larger share of AQST-controlled product economics through assets such as Libervant and, if approved, Anaphylm, while still using manufacturing, licensing, and royalty streams to help fund development. The company has not emphasized a single long-term revenue target in its SEC filings; instead, its public scorecard is milestone-driven: approvals, launches, label expansion, payer access, and efficient funding of the pipeline.
1b. Where does Aquestive Therapeutics play?

Aquestive is not trying to play across all of biopharma. It is focused on known or validated active ingredients, specialty indications, and dosage forms where oral film delivery can solve a real problem. That includes seizure rescue, rare or specialty central nervous system conditions, and severe allergic reactions. Geographically, the company’s operating footprint is primarily U.S.-based. Commercially, it plays in narrow prescriber segments where a small specialist sales effort can matter, and it uses partnerships where direct scale would be inefficient.
1c. How does Aquestive Therapeutics plan to win?

Aquestive plans to win by offering dosage forms that are easier, faster, or more practical to use than incumbent alternatives. Its core idea is that administration format can be a competitive weapon: a buccal or sublingual film may be more portable than a liquid, less intimidating than an injection, or more usable during a neurological event than a swallowed tablet. That makes the company’s differentiation more about patient usability, caregiver convenience, and real-world administration than about discovering a new molecule. The company also appears to favor indications where it can commercialize with a relatively focused field force rather than build a large primary-care infrastructure.
1d. What capabilities must Aquestive Therapeutics have in place?

To execute this strategy, Aquestive needs strong formulation science, transmucosal delivery know-how, taste-masking capability, analytical chemistry, intellectual property management, and U.S. Food and Drug Administration-compliant manufacturing. It also needs regulatory skill in designing studies that prove a new dosage form is clinically credible, plus specialty-pharma capabilities in market access, specialty pharmacy distribution, and caregiver support. Because some of its products involve controlled substances, compliance and handling discipline are especially important.
1e. What management systems does Aquestive Therapeutics require?

Aquestive needs tight portfolio management, rigorous quality systems, disciplined capital allocation, and strong regulatory and pharmacovigilance processes. Since it is a small-cap specialty pharma company with a limited number of major assets, management systems must also enforce prioritization: which programs get funded, which launches are supported, and how manufacturing, reimbursement, and clinical milestones are sequenced against available cash. In other words, execution discipline is as important as scientific innovation.

2. What Are the Current Strategic Initiatives of Aquestive Therapeutics?

As of the company’s 2023 annual reporting and 2024 public updates, Aquestive’s current strategic initiatives are relatively clear and tightly focused.

Launch Libervant in the approved pediatric indication. In April 2024, the U.S. Food and Drug Administration approved Libervant, a diazepam buccal film, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy ages 2 to 5. Commercial work therefore shifted from purely regulatory activity to launch execution, including specialty pharmacy set-up, pediatric neurology outreach, reimbursement, and caregiver education.
Advance Anaphylm toward a regulatory filing and commercial readiness. Anaphylm is Aquestive’s most important pipeline asset because it targets a larger market and addresses a visible unmet need: a needle-free epinephrine option for severe allergic reactions. Public disclosures in 2023 and 2024 emphasized ongoing clinical and regulatory work, FDA interactions, and manufacturing preparation needed to complete the application package. The strategic importance is high because successful approval could materially reshape the company’s revenue mix.
Support and optimize the existing proprietary portfolio. Sympazan remains an established proprietary product in a niche neurology indication. Even if it is not the company’s main valuation driver, it provides commercial infrastructure, market access experience, and product revenue that matter for scale and credibility.
Preserve and maximize partnered product economics. Aquestive has historically derived meaningful revenue from partnered manufacturing, licensing, and royalty arrangements based on its delivery technology. Those streams matter strategically because they help fund pipeline investment without forcing the company to rely entirely on external capital.
Keep capital concentrated on the highest-value late-stage opportunities. Public communications suggest a deliberate preference for focused spending on late-stage, de-risked programs rather than a wide discovery portfolio. That is consistent with the company’s size and with management’s emphasis on near- to medium-term value inflection points.

3. What Is the Business Model of Aquestive Therapeutics?

Aquestive’s business model is a hybrid of specialty pharmaceutical commercialization and drug-delivery platform monetization.

What customers actually buy

Customers buy branded prescription products such as Sympazan and Libervant, but that is only part of the model. Business partners also buy access to Aquestive’s formulation and manufacturing capabilities through supply, licensing, and royalty-bearing arrangements tied to products that use its film technology.

Recurring or repeat-driven versus one-time revenue

The most recurring parts of the model are prescription refills, recurring manufacturing supply, and royalties on partnered products. One-time or lumpy revenue can come from milestones, license payments, or contract changes. That makes AQST’s revenue profile less predictable than a pure pharmaceutical annuity model, but less binary than a pre-revenue biotech.

How pricing power works

Pricing power comes from differentiation in usability and delivery, not from sheer scale. A film formulation may command premium pricing if it solves an administration problem for patients or caregivers. However, this pricing power is constrained by payer management, prior authorization, step therapy, and alternatives such as nasal sprays, tablets, or injectables.

Why the business mix matters

The mix matters because each revenue stream has very different economics. Royalties are typically the highest-margin revenue. Manufacturing and supply revenue can be lower margin but still valuable for cash generation. AQST-owned branded products can carry attractive gross margins at the product level, but they require selling, marketing, medical, and reimbursement infrastructure. As a result, a shift toward proprietary product sales can raise long-term strategic value while depressing near-term operating margins if launch spending rises.

What drives gross margin, operating margin, and cash generation

Gross margin is influenced by product mix, manufacturing efficiency, and the share of revenue coming from royalties versus supplied product. Operating margin depends heavily on research and development expense and launch-related selling, general, and administrative expense. Cash generation is driven by royalty receipts, channel inventory dynamics, working capital needs, and the timing of clinical and regulatory spending.

Revenue model

This is not a subscription business. It is a prescription and licensing model: branded prescription sales, repeat refills, supply agreements, royalties, and occasional milestone or licensing revenue.

4. What Products and/or Services Does Aquestive Therapeutics Sell?

Aquestive sells a focused set of specialty pharmaceutical products and also monetizes its film-delivery technology through partners.

Sympazan. Sympazan is a clobazam oral film indicated for seizures associated with Lennox-Gastaut syndrome. It is important because it gives Aquestive a marketed proprietary neurology product and a direct commercial presence.
Libervant. Libervant is a diazepam buccal film for seizure clusters. Its April 2024 approval for patients ages 2 to 5 made it one of the company’s most important strategic assets because it can expand AQST’s proprietary neurology franchise and potentially broaden over time as regulatory barriers ease in older age groups.
Anaphylm. Anaphylm is not an approved product as of mid-2024, but it is strategically central. It is an epinephrine sublingual film candidate for severe allergic reactions, including anaphylaxis. If approved, it could become the company’s largest internally controlled commercial opportunity.
Partnered film-based products and related services. Aquestive has historically generated revenue from manufacturing, licensing, and royalties tied to partnered products that use its delivery technology. Those arrangements, including long-standing relationships linked to Suboxone sublingual film, have been financially important even though the end-market brand may not carry the AQST name.
Earlier approved or legacy assets. The company has had other approved products in its history, but the clearest strategic emphasis in recent disclosures is on Libervant, Anaphylm, Sympazan, and the economics of its partnered portfolio.

From a business-economics standpoint, partnered revenue has historically mattered disproportionately. From a strategy standpoint, Libervant and Anaphylm matter most because they can shift Aquestive toward more proprietary, AQST-controlled value creation.

5. What Are the Key Competitors or Peers of Aquestive Therapeutics?

Aquestive’s competition is best understood by product category rather than by one perfect corporate comparable. It faces different rivals in seizure rescue, allergy rescue, and oral-film delivery.

Neurelis. Neurelis markets Valtoco, a diazepam nasal spray for seizure clusters. This is one of the most direct competitive references for Libervant.
UCB. UCB markets Nayzilam, a midazolam nasal spray used as a rescue treatment for seizure clusters. It is a substitute therapy in the same broader treatment setting.
ARS Pharmaceuticals. ARS is a direct comparator for Anaphylm because neffy is a needle-free epinephrine nasal spray for severe allergic reactions.
kaléo. kaléo’s Auvi-Q is a branded epinephrine auto-injector and a well-known anaphylaxis competitor, even though it uses an injectable format rather than a film.
Teva Pharmaceuticals. Teva competes in the epinephrine auto-injector market through generic offerings, making it a price-oriented substitute in allergy rescue.
Lundbeck. Lundbeck’s legacy Onfi franchise, along with generic clobazam products, competes indirectly with Sympazan in Lennox-Gastaut syndrome by offering the same active ingredient in more conventional dosage forms.
ITF Pharma. ITF’s Tiglutik, an oral suspension of riluzole, is a formulation-based competitor in the amyotrophic lateral sclerosis setting and illustrates the kind of route-of-administration competition AQST has faced in prior products.
IntelGenx. IntelGenx is not a direct competitor in every marketed indication, but it is a useful peer in oral-film drug delivery and specialty reformulation.

The larger point is that AQST rarely wins by outspending big pharma. It wins, if it wins, by making administration meaningfully better in narrow but valuable therapeutic situations.

6. What Is the Marketing Strategy of Aquestive Therapeutics?

Aquestive’s marketing strategy is consistent with a small specialty pharmaceutical company: targeted, prescriber-focused, and access-driven rather than mass-market. For neurology products, the practical audience includes epileptologists, pediatric neurologists, specialized centers, caregivers, and specialty pharmacies. That favors a relatively small field force, disease-state education, conference presence, and patient-support infrastructure over broad direct-to-consumer spending.

Marketing at Aquestive is therefore closely tied to reimbursement and patient services. In specialty pharma, a product can be clinically attractive and still fail commercially if prior authorization, channel friction, or caregiver onboarding are weak. For Libervant, that makes market access, specialty pharmacy execution, and caregiver education at least as important as brand awareness. For Anaphylm, if approved, the likely marketing task would be to explain where a film-based epinephrine product fits versus auto-injectors and nasal sprays, which implies strong medical education and payer work.

Branding matters, but it is more of a supporting capability than the core differentiator. The real differentiator is the product format and the use case it solves.

7. What Are the Key Customer Segments of Aquestive Therapeutics?

Patients and caregivers in specialty neurology. This includes families managing Lennox-Gastaut syndrome and seizure clusters, where administration ease and portability can be important.
Prescribers and specialist centers. Pediatric neurologists, epileptologists, and related specialty clinicians are central demand drivers for AQST’s neurology franchise.
Allergy and emergency-care stakeholders. For Anaphylm, the relevant future customer ecosystem includes allergists, pediatricians, emergency physicians, schools, caregivers, and patients at risk of severe allergic reactions.
Specialty pharmacies, wholesalers, and distributors. These entities are the direct channel customers for proprietary products and influence speed to therapy and refill persistence.
Commercial partners and licensees. This is an important segment for AQST because partnered manufacturing, supply, and royalty arrangements have historically contributed materially to revenue.
Payers and pharmacy benefit managers. These are not always the booked customer in an accounting sense, but they are critical economic gatekeepers because they shape formulary access and net pricing.

Aquestive is not broadly diversified across dozens of end markets. It is concentrated in a handful of specialty therapeutic settings and a limited set of channel and partner relationships. That creates focus, but also concentration risk.

8. What Is the Sales Model of Aquestive Therapeutics?

Aquestive uses a mixed sales model.

Direct specialty commercialization for AQST-owned brands. Products such as Sympazan, and now Libervant in its approved indication, are sold through a focused U.S. specialty-commercial model. That typically means targeted field selling, market-access contracting, patient-support programs, and distribution through specialty pharmacy and wholesale channels.
Partner-led commercialization for licensed or legacy products. In these arrangements, AQST monetizes technology, manufacturing, and royalties while the partner owns most of the broader commercial infrastructure.
Business-to-business revenue for supply and licensing. Some of the company’s revenue is effectively B2B rather than patient-facing, because it comes from commercial counterparties that buy manufactured product, rights, or technology access.

This channel structure affects growth and economics in important ways. A targeted direct model can produce strong customer intimacy in small specialist markets without the cost of a national primary-care sales force. But it also means each launch has to be highly disciplined, because a few channel decisions can materially influence uptake. That same structure creates clear consultant opportunities in market access, specialty pharmacy design, launch planning, and partner economics.

9. In What Geographies Does Aquestive Therapeutics Operate?

Aquestive’s operating center of gravity is the United States. Its headquarters are in Warren, New Jersey, and its key manufacturing footprint is in Portage, Indiana. Commercially, its proprietary products are primarily U.S.-focused, and the company does not appear to operate a broad owned international sales network.

That does not mean the company is purely domestic in economic reach. Some partnered and licensed product relationships extend AQST’s technology and revenue base beyond the United States. But this is mostly an indirect international model, with partners carrying local commercialization responsibilities rather than AQST building full country organizations.

The practical implication is that geographic diversification is limited. AQST is more concentrated than a multinational pharmaceutical company, but it also avoids much of the overhead that comes with a global direct-sales footprint.

10. Who Are the Owners of Aquestive Therapeutics?

Aquestive is a publicly traded company listed on Nasdaq under the ticker AQST. As of the company’s 2024 proxy disclosures, it did not report a controlling shareholder. Ownership appears primarily institutional, which is typical for a small-cap biotech and specialty pharmaceutical company. Public filings in 2024 indicated that specialist investment managers, including TCG Crossover Management and Rubric Capital Management, were among the notable large shareholders. The shareholder base can change meaningfully over time, so the current proxy statement and recent Schedule 13G filings are the right places to confirm up-to-date positions.

11. How Is Aquestive Therapeutics Organized?

Officially, Aquestive reports one operating segment. Practically, however, the company is organized around a few distinct activities:

Commercial. Proprietary product sales, market access, medical affairs support, specialty distribution, and patient services.
Research and development. Formulation science, clinical development, regulatory affairs, and pipeline program management.
Operations. Manufacturing, quality assurance, quality control, supply chain, packaging, and distribution support.
Partnered business management. Licensing, supply agreements, royalties, and alliance management for products sold by third parties.
Corporate functions. Finance, legal, compliance, human resources, and investor relations.

This is a fairly typical structure for a specialty pharma company that has both proprietary products and platform-based partner revenue. The notable feature is that one legal/reporting segment contains two fairly different economic engines: AQST-owned brands and partner-linked revenue streams.

12. How Does Aquestive Therapeutics Operate?

On a day-to-day basis, Aquestive operates as a formulation-driven specialty pharmaceutical company.

Select indications where delivery format matters. The company chooses therapeutic situations where a thin film can improve administration, convenience, or caregiver usability.
Develop the formulation and prove it analytically and clinically. That includes film composition, dose uniformity, taste masking, stability, absorption, and the pharmacokinetic profile needed for regulatory approval.
Manufacture under current good manufacturing practice standards. AQST must source active pharmaceutical ingredients and excipients, convert film into finished dosage forms, package it, test it, and release it under strict quality controls.
Commercialize through specialty channels or partners. Proprietary products go through focused specialty-pharma channels; partnered products are supplied to or commercialized by third parties.
Manage reimbursement, safety, and lifecycle issues. As with any prescription pharmaceutical company, market access, pharmacovigilance, compliance, and post-approval quality systems are part of routine operations.

The operational complexity is not about massive manufacturing scale. It is about precision, regulatory compliance, stability, and dependable supply in niche but clinically sensitive products. A single manufacturing or quality problem can have outsized consequences when the portfolio is concentrated.

13. What Are the Growth Opportunities for Aquestive Therapeutics?

The most plausible growth opportunities for Aquestive are concentrated in a small number of assets and strategic moves.

Anaphylm approval and launch. This is the clearest high-upside opportunity because it targets a visible market with established demand and could create a differentiated, needle-free offering.
Libervant commercialization and eventual age expansion. The approved pediatric indication gives AQST an initial foothold. A reasonable external synthesis is that broader commercialization opportunities would improve materially if regulatory exclusivity barriers in older age groups change over time.
Deeper penetration of Sympazan. Growth here is likely more incremental than transformational, but better physician awareness, channel execution, and persistence could still matter.
Additional partnered products using AQST’s delivery technology. This could create relatively capital-light growth if the company signs more licensing or development relationships rather than funding everything internally.
International licensing. Because AQST does not have a broad ex-U.S. commercial infrastructure, partnerships could be a practical way to expand the reach of approved or future products.
Lifecycle management and adjacent indications. The company’s formulation expertise may support line extensions or adjacent use cases where oral-film delivery offers a clear benefit.

The main constraints are equally clear: regulatory timing, payer access, competition from nasal or injectable alternatives, product concentration, and the need to fund launches and development without overstretching the balance sheet.

14. What Is the History of Aquestive Therapeutics?

Aquestive’s roots go back to 2004, when the business was founded around oral film drug-delivery technology. The company developed the PharmFilm platform to administer medicines through thin films rather than conventional tablets or liquids. In 2016, the business adopted the Aquestive Therapeutics name, reflecting a broader push to build a specialty pharmaceutical company around that technology base.

Aquestive became a public company in 2018 through its initial public offering on Nasdaq. Around that period, it began to build a more visible proprietary product portfolio, including Sympazan, which was approved in 2018. Exservan followed in 2019. The company also participated in partnered and licensed products, which helped establish manufacturing and royalty revenue streams alongside proprietary development.

The company’s history also includes examples of the volatility typical of small specialty pharma firms. Some products achieved approval but remained commercially niche, and partner priorities could change. A useful example is Kynmobi, an apomorphine sublingual film that was approved and commercialized by a partner but later discontinued. More recently, Libervant’s regulatory path was shaped by orphan-drug exclusivity held by a competing product, delaying broader commercialization. Its April 2024 approval for ages 2 to 5 was therefore an important milestone. By 2024, the company’s next major chapter was clearly centered on Libervant execution and Anaphylm development.

15. How Does the Supply Chain of Aquestive Therapeutics Function?

The supply chain is strategically important for Aquestive because the company’s value proposition depends on reliable, precisely manufactured dosage forms rather than commodity tablets. The process starts with sourcing active pharmaceutical ingredients, excipients, film-forming materials, packaging components, and analytical testing inputs. These materials then flow into AQST’s manufacturing operations, where films are produced, converted, cut, packaged, tested, and released under current good manufacturing practice standards.

Several features make this supply chain more sensitive than it may look from the outside. First, some AQST products involve controlled substances, which adds security, documentation, and compliance requirements. Second, small specialty products can still have high service-level expectations; if one product has limited alternative supply, a disruption can materially affect patients and prescribers. Third, thin-film dosage forms require tight control over uniformity, stability, and packaging integrity.

As with many specialty pharma companies, supplier concentration and single-source components appear to be relevant risks in SEC disclosures. That means procurement resilience, inventory planning, and quality oversight are important management disciplines, not back-office details.

16. What Are the Key Assets of Aquestive Therapeutics?

Aquestive is asset-intensive in a pharmaceutical sense, though not in the same way as a large-scale manufacturer with dozens of plants. Its most important assets are:

PharmFilm intellectual property and know-how. The company’s formulation science, manufacturing methods, and patent estate are central to its competitive position.
Approved product dossiers and regulatory rights. Sympazan, Libervant, and other approved or previously approved assets carry value through their regulatory status, data packages, and commercial rights.
Pipeline assets, especially Anaphylm. In a small specialty pharma company, late-stage pipeline assets are often among the most important economic assets on the balance sheet, whether or not their full value is recognized in accounting terms.
Manufacturing capability in Portage, Indiana. Owning and operating specialized manufacturing capacity matters because AQST’s dosage forms are not generic off-the-shelf products.
Partner agreements and royalty interests. These contractual assets can provide recurring cash flow and help fund proprietary growth.

For AQST, barriers to entry come more from know-how, regulatory execution, and intellectual property than from sheer physical scale.

17. What Is the Technology Strategy of Aquestive Therapeutics?

Aquestive’s technology strategy is mainly about pharmaceutical delivery technology, not enterprise software. The company is trying to make the dosage form itself a source of competitive advantage. PharmFilm is the center of that strategy: a platform for delivering medicines through oral soluble, buccal, and sublingual films that can be easier to administer than tablets, liquids, or injectables in certain use cases.

This technology strategy has two dimensions. First, it is an internal enabler: better formulation science, analytical methods, dose uniformity, taste masking, and manufacturing control help AQST move programs from concept to approval. Second, it is part of the customer offering: the film format is often the main reason a product is differentiated in the market.

That is especially important in AQST’s chosen indications. In seizure rescue and severe allergic reactions, usability and speed are not secondary features; they can determine whether a product is adopted. The company’s public positioning suggests it believes delivery innovation can create defensible value even when the active ingredient itself is already well understood.

18. What Is the R&D Strategy of Aquestive Therapeutics?

Aquestive’s research and development strategy is more formulation-centric than discovery-centric. It is not trying to compete with large biotech companies in novel target discovery. Instead, it focuses on reformulating known medicines into dosage forms that solve administration problems, support patient adherence, or improve usability in urgent situations.

That changes the shape of R&D work. AQST still has to invest meaningfully in clinical development, regulatory strategy, human factors, chemistry, manufacturing and controls, and stability testing. But the scientific risk profile can be different from a new molecular entity program, because the active ingredient is often already clinically validated. The challenge is proving that the new route of administration works reliably and supports the intended use case.

Public disclosures indicate that late-stage programs such as Anaphylm and the Libervant franchise have been the main R&D priorities. The company’s R&D strategy therefore appears intentionally selective: spend behind a few assets with clear commercial logic, rather than spread resources across a broad early-stage pipeline.

19. What Is the Finance Strategy of Aquestive Therapeutics?

Aquestive’s finance strategy is shaped by a familiar small-cap specialty pharma challenge: it has meaningful commercial opportunities, but it must sequence them carefully against limited capital. The company does not operate a dividend model and is not managed for near-term yield. Cash is primarily reinvested into product development, launch readiness, manufacturing support, and corporate infrastructure needed to get late-stage assets to market.

The practical pillars of the finance strategy appear to be:

Use existing product, supply, licensing, and royalty revenue to offset pipeline burn.
Keep the portfolio focused so capital is concentrated on late-stage, value-inflecting assets.
Manage liquidity conservatively around regulatory and launch milestones.
Access external capital when needed, but avoid overbuilding fixed cost ahead of revenue.

An important implication is that finance strategy and portfolio strategy are tightly linked. For AQST, deciding what to fund is effectively the same as deciding what kind of company it can become over the next several years.

20. How Companies Like Aquestive Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. Companies like Aquestive use Umbrex when they need that caliber of problem-solving talent but do not need a full traditional consulting team with the associated overhead. For a specialty pharmaceutical company such as AQST, the most valuable projects are usually highly focused, milestone-driven, and cross-functional across strategy, operations, commercialization, finance, technology, ERP, and AI.

Libervant launch acceleration. Refine pediatric neurology targeting, caregiver journey design, launch metrics, and early market-access priorities.
Anaphylm commercialization readiness. Build indication-specific go-to-market scenarios, physician-segmentation logic, payer strategy, and adoption forecasting ahead of approval.
Pricing, reimbursement, and gross-to-net strategy. Assess list price architecture, prior-authorization friction points, copay strategy, and specialty-pharmacy economics for rescue therapies.
Portfolio prioritization and capital allocation. Create a stage-gate framework to compare late-stage pipeline investments, commercial support levels, and business-development options.
Manufacturing and supply-chain risk review. Stress-test single-source dependencies, inventory policies, quality-release timing, and launch-readiness planning for specialty products.
Partnered-product and royalty optimization. Review contract economics, demand planning, and management dashboards for supply and royalty-bearing relationships.
Specialty pharmacy and patient-support redesign. Improve onboarding, refill persistence, prior-authorization conversion, and caregiver communication processes.
International licensing strategy. Identify priority ex-U.S. markets, design partner-selection criteria, and support licensing outreach for assets such as Anaphylm or Libervant.
Commercial organization design. Help AQST adapt its structure as it shifts from a partner-heavy revenue mix toward a larger proprietary commercial footprint.
Financial planning and investor-readiness analytics. Build milestone-based cash scenarios, launch sensitivity models, and decision support for financing and capital planning.